Atea Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2021
August 12, 2021 at 04:05 pm EDT
Share
Atea Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported collaboration revenue of $60,391,000. Income from operations was $8,687,000 against loss of $10,003,000 a year ago, net income of $1,539,000 against loss of $9,993,000 a year ago and net income per share, basic and diluted was $0.02 against loss per share of $0.99 a year ago.
For the six month, the company reported collaboration revenue of $126,376,000. Income from operations was $39,343,000 against loss of $14,048,000 a year ago, net income of $32,252,000 against loss of $13,981,000 a year ago and net income per share, basic was $0.39 against loss per share of $1.39 a year ago. Net income per share, basic was $0.36 against loss per share of $1.39 a year ago.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.
ATEA PHARMACEUTICALS, INC. 
